

DNDi

Drugs for Neglected Diseases *initiative*



DNDi@WorldLeish6

#worldleish6

6th World Congress on Leishmaniasis
Toledo, Spain - 16-20 May, 2017





TUESDAY, 16 MAY 2017

Parallel Sessions @ 11:30-13:00		> Toledo room
PKDL	Chairs: Ed Zijlstra (DNDi, Geneva, Switzerland) Shyam Sundar (Varanasi University, India)	
<i>PKDL an overview of clinical aspects</i>	Ahmed Musa (Institut of Endemic Diseases, University of Khartoum, Sudan)	
<i>Special forms of PKDL</i>	Venkatesh Ramesh (Safdarjung Hospital, New Delhi, India)	
<i>Advances in understanding of immunobiology of PKDL</i>	Poonam Salotra (Indian Council of Medical Research, New Delhi, India)	
<i>PKDL insights in transmission</i>	Dinesh Mondal (ICDDRDB, Dhaka, Bangladesh)	

Parallel Sessions @ 14:00-15:30		> Toledo room
The present and future of VL treatment	Chairs: Fabiana Alves (DNDi, Geneva, Switzerland) Ahmed Musa , (Institute of Endemic Diseases, University Khartoum, Sudan)	
<i>Treatment of VL: the African case</i>	Robert Kimutai (DNDi, Nairobi, Kenya)	
<i>Current knowledge and needs for VL treatment in Brazil</i>	Gustavo Romero (Universidade de Brasilia, Brasil)	
<i>New insights into the exposure-response relationships for miltefosine in the treatment for VL</i>	Thomas Dorlo (The Netherlands Cancer Institute, Amsterdam, Netherlands)	
<i>Perspectives for improved treatments on VL</i>	Fabiana Alves (DNDi, Geneva, Switzerland)	



6th World Congress on Leishmaniasis, Toledo, Spain, 16-20 May, 2017

Oral Communications Sessions @ 11:30-13:00

> Miradero Room

Oral communications session 2

Diagnostic methodology in practice and under development

Biomarkers in leishmaniasis

Oral Communications Sessions @ 15:00-16:00

> Miradero Room

Oral communications session 4

Mucocutaneous leishmaniasis

Diffuse cutaneous leishmaniasis

Post kala-azar leishmaniasis

Oral Communications Sessions @ 15:30-17:00

> Room C1-C2

Oral communications session 5

Drug development: conventional and alternative

Clinical and experimental therapy in CL and VL



Satellite Symposium @ 16:00-17:30

> Auditorium

Supported by **Marca España** and Sponsored by RICET (Spanish Network for Research in Tropical Diseases) and SEMTSI (Spanish Society of Tropical Medicine and International Health)

Landscape of Spanish research in leishmaniasis

Chairs:

Luis Rivas (CSIC)

Jorge Alvar (DNDi, Geneva, Switzerland)

Applied research at the WHO Collaborating Center of Leishmaniasis, a 20 year endeavour

Javier Moreno (ISCIII)

Basic research at the CSIC

Dolores González Pacanowska (IPB-CSIC)

Clinical research & international cooperation

Nines Lima (MSF-Spain)

Canine leishmaniasis research at university

Guadalupe Miró (UCM)

Coffee Break @ 17:30-18:00

> Greco room A

DNDi Drug Booster -

Project of the Year Awards 2016



WEDNESDAY, 17 MAY 2017

Parallel Sessions @ 09:30-11:00		> Toledo room
Non-invasive field adapted tools (and biomarkers) for VL diagnosis and test of cure	Chairs: Israel Cruz (FIND, Geneva, Switzerland) Anabela Cordeiro (Universidade do Porto, Porto, Portugal)	
<i>Challenges and progress toward a simple point of care diagnostic test for VL in East Africa</i>	Maowia Mukhtar (Institute of Endemic Diseases, University of Khartoum, Sudan)	
<i>RDTs and diagnostic algorithms in the management of persistent fever syndrome in VL endemic areas</i>	François Chappuis (University of Geneva, Geneva, Switzerland)	
<i>Development of prognostic serological biomarkers for VL and their relevance to disease control</i>	Michael Miles (London School of Hygiene and Tropical Medicine, London, UK)	
<i>The diagnostic challenges and needs in the kala-azar elimination programme in South Asia</i>	Suman Rijal (DNDi, India)	

Parallel Sessions @ 14:00-15:30		> Toledo room
VL drug discovery	Chairs: Charles Mowbray (DNDi, Geneva, Switzerland) Mitsuyuki Shimada (Takeda, Japan)	
<i>The A to Z of drug discovery for visceral leishmaniasis</i>	Kevin Read (Drug Discovery Unit, Dundee University, Dundee, UK)	
<i>Kinetoboxes: the beginning of a beautiful friendship</i>	María Marco-Martín (GlaxoSmithKline, Madrid, Spain)	
<i>Novel antileishmanial agents: amino-pyrazole ureas with potent in vitro and in vivo activity</i>	Paul A Glossop (Sandexis, UK)	
<i>Discovery and optimisation of a new class of potent antileishmanial compounds and determination of their mechanism of action</i>	Frantisek Supek (Genomics Institute of the Novartis Research Foundation, San Diego, US)	



Parallel Sessions @ 14:00-15:30

> Greco room C1-C2

Outbreak assessment & surveillance

Chairs:

Piero Olliaro (WHO/TDR, Geneva, Switzerland)

Suman Rijal (DNDi, India)

Oral Communications Sessions @ 09:30-11:00

> Miradero Room

Oral communications session 5

Drug development: conventional and alternative

Clinical and experimental therapy in CL and VL

Oral Communications Sessions @ 15:30-17:00

> Miradero Room

Oral communications session 12

Epidemiology

Satellite Symposium @ 16:00-18:00

> Auditorium

Sponsored by Thermosurgery Technologies

An overview of thermotherapy for the treatment of cutaneous leishmaniasis

Chairs:

Abhay Satoskar (Wexner Medical Center, The Ohio State University, Columbia, US)

Introduction and overview of thermotherapy

Gena Zischke (Thermosurgery technologies, US)

Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials

Ivan D Velez (PECET, Medellín, Colombia)

Longterm efficacy of radio-frequency Heat therapy in cutaneous leishmaniasis caused by *L. tropica* in India

RA Bumb (SP Medical College, Bikaner, Rajasthan, India)

Treatment of displaced populations or in conflict areas

Najibullah Safi (MoPH, Afganistan)

The immunology of a healing response in cutaneous leishmaniasis treated with localized heat therapy

Ines Elakhal Naouar (PhD) and Naomi Aronson (Uniformed Services University of the Health Sciences, Bethesda, US)

Thermotherapy plus miltefosine for the treatment of cutaneous leishmaniasis

Byron Arana (DNDi, Geneva, Switzerland)



Poster Presentations @ 16:30-19:30

Early drug discovery

Animal models and genetic susceptibility

Drug resistance mechanisms

Panel 239 ► 1570

Translational challenges in Visceral Leishmaniasis drug development: Different models, different drugs' mechanism of action, different predictive value: Towards an emerging answer?

Panel 240

One step towards an oral treatment for cutaneous leishmaniasis: the in vivo efficacy of three chemical classes under preclinical development for visceral leishmaniasis

Panel 238

Large-scale screening effort to identify new chemical starting points for visceral leishmaniasis using a novel in vitro screening cascade

Panel 230

Searching for new antileishmanials in endemic areas: hit-to-lead activities within DNDi's lead optimization Latin America consortium

Drug development: conventional and alternative

Clinical and experimental therapy in cutaneous and visceral leishmaniasis

Panel 135 ► C1568

DNDI-0690: A new promising drug candidate for the treatment of visceral leishmaniasis

Panel 136 ► C1571

DNDI-6148: a new potential clinical candidate to treat visceral leishmaniasis

Panel 146 ► C1679

Safety and efficacy of miltefosine allometric dose for the treatment of children with primary visceral leishmaniasis in Eastern Africa

Panel 155 ► C1796

Supporting policy change by conducting a phase IV effectiveness and safety study in limited-resource settings in Bihar

Panel 115 ► C1385

Safety and effectiveness of SSG & PM combination for the treatment of visceral leishmaniasis in Eastern Africa: results from a pharmacovigilance programme



THURSDAY, 18 MAY 2017

Parallel Sessions @ 11:30-13:00

➤ Toledo room

Cutaneous leishmaniasis treatment and pipeline drugs

Chairs:

Max Grögl (U.S. Naval Medical Research Unit No. 6, Lima, Peru)

Elizabeth Valdivieso (Universidad Central Caracas, Venezuela)

Current recommendations for treating CL worldwide

Afif Bensalah (Arabian Gulf University, Bahrain)

CL treatment: clinical developments

Byron Arana (DNDi, Geneva, Switzerland)

CL R&D pipeline

Charles Mowbray (DNDi, Geneva, Switzerland)

Harmonised clinical trial methodologies for CL

Piero Olliaro (WHO/TDR, Geneva, Switzerland)

Oral Communications Sessions @ 11:30-13:00

➤ Greco Room D1-D2

Oral communications session 15

Early drug discovery

Animal models and genetic susceptibility

Drug resistance mechanisms

Oral Communications Sessions @ 11:30-13:00

➤ Miradero Room

Oral communications session 16

Clinical and experimental immunopathology and pathogenesis

Oral Communications Sessions @ 15:30-17:00

➤ Greco Room C1-C2

Oral communications session 19

Operational research



6th World Congress on Leishmaniasis, Toledo, Spain, 16-20 May, 2017

Consensus Symposium @ 18:30-19:30

> Auditorium

Roadmap for cutaneous leishmaniasis drugs

Conducted by:

Simon Croft (London School of Hygiene and Tropical Medicine, UK)

Byron Arana (DNDi, Geneva, Switzerland)

Where are we for cutaneous leishmaniasis R&D?

Simon Croft (LSHTM) and **Byron Arana** (DNDi, Geneva, Switzerland)

So what do we need?

Charlie Mowbray (DNDi, Geneva, Switzerland)

How do we do it?

Katrien van Bocxlaer (LSHTM, UK) and **Sima Rafati** (Institut Pasteur, France)

Satellite Symposium @ 18:00-19:30

> Toledo room

Organized by Mundo Sano and DNDi and Sponsored by Mundo Sano.

Communication and neglected tropical diseases: an illustration with leishmaniasis and other NTDs

Chairs:

Irene Tato (Mundo Sano)

Jean François Alesandrini (DNDi, Geneva, Switzerland)

Emilio de Benito (El País, Chair of ANIS, Spanish Association of Health Journalists)

Antonio Calvo Roy (Chair of the AECC, Spanish Association of Scientific Communicators)

Talha Burki (The Lancet, UK)

Verah Okeyo (Daily Nation, Kenya)

Nora Bär (La Nación, Argentina)

Franziska Badenschier (European Science Journalists, Germany)



Poster Presentations @ 16:30-19:30

Diagnostic methodology in practice and under development. Biomarkers in leishmaniasis

Panel 274 ➤ C1644

Comparative evaluation of diagnosis of post kala-azar dermal leishmaniasis by qPCR, microscopy and rK39 in cohort of Kala Azar patients treated with three new treatment regimens

Panel 286 ➤ C1799

Development of an antigen detection test in urine for the diagnosis of active visceral leishmaniasis

Clinical and experimental prophylactic and therapeutic vaccination. Clinical and experimental immunology

Panel 154 ➤ C1727

Treatment of visceral leishmaniasis patients outside clinical trials; the case of the Leishmaniasis East Africa Platform



FRIDAY, 19 MAY 2017

Satellite Symposium & Special Parallel Session @ 16:00-17:30

➤ Auditorium

Students and masters talking out of the box

Masters:

Graeme Bilbe (DNDi Geneva, Switzerland)

Carlos Costa (Universidade Federal do Piauí, Teresina, Brazil)

Rhea Coler (Washington University, US)

Students:

Temmy Sumyoto (Euroleish programme, Indonesia)

Joana Pissarra (Euroleish programme, Portugal)

Rezika Mohammed (DNDi, Africa)

Inés Martín (NIH, Spain)

Oral Communications Sessions @ 11:30-13:00

➤ Greco Room C1-C2

Oral communications session 23

Control programs

National and international funding organizations

Oral Communications Sessions @ 15:00-16:00

➤ Miradero Room

Oral communications session 25

Leishmania co-infection



Consensus Symposium @ 16:00-19:30

➤ Auditorium

Advocating for the future

Conducted by:

Jorge Alvar (Chair of Worldleish 6)

Alejandro Gaviria (Minister of Health,
Colombia)

Mercedes Tatay, (International Medical
Secretary of Médecins Sans Frontières)

Bernard Pécoul, (Executive Director, DNDi)

Poster Presentations @ 16:30-19:30

Operational research

Panel 238 ➤ C1550

The economic impact of visceral leishmaniasis
in Baringo

Leishmania HIV co-infection

Panel 202 ➤ C1678

Treatment relapse at baseline: impact on
unplanned visits in a randomized clinical trial of
HIV/VL co-infection treatment for patients in
Ethiopia

Control programs

Panel 37 ➤ C1542

**National and international funding
organizations**

Aggregation of patient level data for routine
reporting using DHIS2 tracker module for VL
surveillance



SATURDAY, 20 MAY 2017

Plenary Session 4 @ 08:00-09:30		> Auditorium
Access to treatment	Conducted by:	
	Margriet den Boer (Médecins Sans Frontières)	
Panelists:	Bernard Pécoul (DNDi, Geneva, Switzerland)	
	Robert Sebbag (Former Vice President Access to Medicines, Sanofi-Aventis)	
	JA Ruiz-Postigo (WHO/Leishmaniasis programme, Geneva, Switzerland)	
	Nirmal Kumar Ganguly (Visiting professor of eminence Translational Health Science & Technology Institute NCR Biotech Science Cluster, Faridabad, India)	
	Judy Stone (Contributor, Pharma and Health for Forbes, US)	
Parallel Sessions @ 09:30-11:00		> Auditorium
Challenges on implementation and development of clinical trials	Chairs:	
	Nathalie Strub-Wourgaft (DNDi, Geneva, Switzerland)	
	Jane Mbuy (KEMRI, Nairobi Kenya)	
Methodology and study design	Vishal Goyal (DNDi, India)	
Good clinical practices	Varalakshmi Elango (Former WHO/TDR)	
From clinical trials to access	Nathalie Strub-Wourgaft (DNDi, Geneva, Switzerland)	



Oral Communications Sessions @ 09:30-11:00

> Miradero Room

Oral communications session 27

Control programs

National and international funding organizations

Parallel Sessions @ 09:30-11:00

> Greco room C1-C2

Platforms for research and control

Chairs:

Monique Wasunna (DNDi, Nairobi, Kenya)

Jorge Alvar (DNDi, Geneva, Switzerland)

The Leishmaniasis East African Platform: contributing to strengthening clinical trial capacity, treatment and control of visceral leishmaniasis in Eastern Africa

Asrat Hailu (University of Addis Ababa, Addis Ababa, Ethiopia)

Leishmaniasis research network (RedLeish): experience in Latin America

Joelle Rode (DNDi, Rio de Janeiro, Brazil)

Building a joint effort to optimally assess the efficacy of visceral leishmaniasis therapies: a VL data repository and network

Philippe Guerin (Oxford University, Oxford, UK)

Kalacore-Bi regional support for the control and elimination of visceral leishmaniasis in Africa and Asia: developing an integrated approach to implementation and research

Simon Croft (London School of Hygiene and Tropical Medicine, London, UK)



6th World Congress on Leishmaniasis, Toledo, Spain, 16-20 May, 2017

Awards @ 11:30-12:00

> Auditorium

Photography Contest

PLOS Collection Papers

Tributes:

- Prof CP Thakur
- Prof AM El Hassan

Homage:

- Prof Rioux

#worldleish6



facebook.com/dndi.org



twitter.com/dndi



instagram.com/drugsforneglecteddiseases



linkedin.com/company/dndi



youtube.com/dndiconnect



Subscribe to DNDi's newsletter: www.dndi.org/newsletter

DNDi HEADQUARTERS

15 Chemin Louis-Dunant
1202 Geneva
Switzerland
Tel: +41 22 906 9230
Fax: +41 22 906 9231
Email: dndi@dndi.org

DNDi NORTH AMERICA

40 Wall Street, 24th Floor
New York, NY 10005
USA
Tel: +1 646 616 8680
www.dndina.org

DNDi AFRICA

Tetezi Towers, 3d Floor
George Padmore Road
Kilimani
P.O. Box 21936-00505
Nairobi
Kenya
Tel: +254 20 3995 000

DNDi LATIN AMERICA

Rua Santa Heloisa 5
Jardim Botânico
Rio de Janeiro – RJ
22460-080
Brazil
Tel: +55 21 2529 0400
www.dndial.org

DNDi INDIA

PHD House, 3rd Floor
4/2 Siri Institutional Area
New Delhi 110016
India
Tel: +91 11 4550 1795

DNDi JAPAN

704 Nishi-Shinjuku KF Bldg
8-14-24 Nishi-Shinjuku, Shinjuku-ku
Tokyo 160-0023
Japan
Tel: +81 3 4550 1199
Fax: +81 3 5937 6977
www.dndijapan.org

DNDi South East Asia

L10-7, Menara Sentral Vista,
150, Jln Sultan Abdul Samad
Brickfields
50470 Kuala Lumpur
Malaysia
Tel: +60 3 2716 4159

DNDi DRC

Avenue Milambo, n°4
Quartier Socimat
Commune de la Gombe
Kinshasa
Democratic Republic of the Congo
Tel: +243 81 659 79 95

DNDi

Drugs for Neglected Diseases *initiative*

15 Chemin Louis-Dunant, 1202 Geneva, Switzerland
Tel: +41 (0) 22 906 9230 ; Fax: +41 (0) 22 906 9231
dndi@dndi.org ; www.dndi.org